From Wikipedia, the free encyclopedia
  (Redirected from Plenaxis)
Jump to: navigation, search
Systematic (IUPAC) name
acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
Clinical data
Trade names Plenaxis
AHFS/Drugs.com monograph
  • US: X (Contraindicated)
Intramuscular injection
Pharmacokinetic data
Protein binding 96–99%
183552-38-7 N
PubChem CID 16131215
IUPHAR ligand 1188
DrugBank DB00106 YesY
ChemSpider 10482301 YesY
UNII W486SJ5824 YesY
KEGG D02738 YesY
ChEBI CHEBI:337298 YesY
Chemical data
Formula C72H95ClN14O14
1416.06 g/mol
 N (what is this?)  (verify)

Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[1][2]

It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[1] and is now marketed by Speciality European Pharma in Germany[3] after receiving a marketing authorisation in 2005.


  1. ^ a b Drugs.com: Abarelix
  2. ^ Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology 3 (3): 127–140. doi:10.1177/1756287211414457. PMC 3159401. PMID 21904569.  edit
  3. ^ Pharmazeutische Zeitung online: Abarelix (German)